Eric P. Lefkofsky Sells 250,000 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric P. Lefkofsky sold 250,000 shares of the firm's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $70.07, for a total transaction of $17,517,500.00. Following the completion of the sale, the chief executive officer now directly owns 9,357,283 shares of the company's stock, valued at approximately $655,664,819.81. The trade was a 2.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Price Performance

Shares of Tempus AI stock traded down $0.79 during trading hours on Friday, reaching $68.31. 7,016,268 shares of the company's stock were exchanged, compared to its average volume of 7,094,385. The company has a market capitalization of $11.83 billion and a P/E ratio of -8.76. The business has a fifty day moving average of $58.73 and a two-hundred day moving average of $52.71. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45. The company has a quick ratio of 1.56, a current ratio of 1.71 and a debt-to-equity ratio of 2.45.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.03. The company had revenue of $255.74 million for the quarter, compared to analyst estimates of $248.13 million. Tempus AI had a negative net margin of 88.27% and a negative return on equity of 533.21%. Tempus AI's revenue for the quarter was up 75.4% compared to the same quarter last year. As a group, research analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Guggenheim restated a "buy" rating on shares of Tempus AI in a report on Tuesday, February 25th. Wolfe Research cut Tempus AI from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. BTIG Research initiated coverage on shares of Tempus AI in a research report on Monday, April 21st. They set a "buy" rating and a $60.00 price target for the company. JPMorgan Chase & Co. cut shares of Tempus AI from an "overweight" rating to a "neutral" rating and raised their price target for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Finally, Bank of America lifted their price target on shares of Tempus AI from $48.00 to $68.00 and gave the stock a "neutral" rating in a report on Tuesday, May 20th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $63.42.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new position in shares of Tempus AI in the 4th quarter valued at approximately $216,000. Wells Fargo & Company MN boosted its stake in shares of Tempus AI by 13.2% during the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company's stock worth $80,000 after acquiring an additional 278 shares in the last quarter. SeaCrest Wealth Management LLC acquired a new position in Tempus AI during the first quarter worth $535,000. ProShare Advisors LLC purchased a new stake in Tempus AI during the fourth quarter worth $244,000. Finally, Avanza Fonder AB increased its position in shares of Tempus AI by 15.8% in the first quarter. Avanza Fonder AB now owns 41,005 shares of the company's stock valued at $2,047,000 after buying an additional 5,591 shares in the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.